Abstract
Objectives: As a selective matrix metalloproteinase inhibitor, MMI-166 specifically inhibits MMP-2 and MMP-9 activity and represses tumor invasion and metastasis. Previous studies show that MMI-166 has an anti-metastatic role in a variety of tumors. However, it still remains unclear about the exact effect of MMI-166 on human pancreatic cancer.
Methods: In this study, we showed firstly MMI-166 induced proliferation inhibition and apoptosis of SW1990 human pancreatic cancer cells in both dose- and time-dependent manners in vitro. We successfully established a human pancreatic cancer xenograft model in nude mice and verified the inhibition effect of MMI-166 on MMP-2 and MMP-9.
Results: More importantly, by using this model, we further demonstrated MMI-166 suppressed growth of SW1990 pancreatic cells xenograft in vivo by inducing cells apoptosis. In addition, we examined the expression of a series of apoptosis-related proteins and found MMI-166 inhibited the expression of c-Myc.
Conclusion: Our work demonstrates that MMI-166 may be of therapeutic value in the treatment of pancreatic cancer.
Keywords: Animal experimentation, apoptosis, cell proliferation, MMI-166, pancreatic neoplasms.
Graphical Abstract
Current Signal Transduction Therapy
Title:Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells
Volume: 9 Issue: 2
Author(s): Junben Wu, Muhammad Shahbaz, Shujing Wang, Bengang Gong, Benjia Liang, Ruliang Fang, Bo Qiu, Min Jiang, Yang Li and Jun Niu
Affiliation:
Keywords: Animal experimentation, apoptosis, cell proliferation, MMI-166, pancreatic neoplasms.
Abstract: Objectives: As a selective matrix metalloproteinase inhibitor, MMI-166 specifically inhibits MMP-2 and MMP-9 activity and represses tumor invasion and metastasis. Previous studies show that MMI-166 has an anti-metastatic role in a variety of tumors. However, it still remains unclear about the exact effect of MMI-166 on human pancreatic cancer.
Methods: In this study, we showed firstly MMI-166 induced proliferation inhibition and apoptosis of SW1990 human pancreatic cancer cells in both dose- and time-dependent manners in vitro. We successfully established a human pancreatic cancer xenograft model in nude mice and verified the inhibition effect of MMI-166 on MMP-2 and MMP-9.
Results: More importantly, by using this model, we further demonstrated MMI-166 suppressed growth of SW1990 pancreatic cells xenograft in vivo by inducing cells apoptosis. In addition, we examined the expression of a series of apoptosis-related proteins and found MMI-166 inhibited the expression of c-Myc.
Conclusion: Our work demonstrates that MMI-166 may be of therapeutic value in the treatment of pancreatic cancer.
Export Options
About this article
Cite this article as:
Wu Junben, Shahbaz Muhammad, Wang Shujing, Gong Bengang, Liang Benjia, Fang Ruliang, Qiu Bo, Jiang Min, Li Yang and Niu Jun, Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells, Current Signal Transduction Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574362409666141201202706
DOI https://dx.doi.org/10.2174/1574362409666141201202706 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors
Current Pharmaceutical Design Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Nerve Growth Factor: Early Studies and Recent Clinical Trials
Current Neuropharmacology Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology Hypoxia in Du-145 Prostate Cancer Xenografts After Estramustine Phosphate and Radiotherapy
Current Radiopharmaceuticals Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Current Drug Targets Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response
Current Gene Therapy Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition Synthesis and Biological Evaluation of 2´-Hydroxy-4´,6´-Diprenyloxychal-Cone Derivatives as Potent CDC25B and PTP1B Inhibitors
Letters in Drug Design & Discovery Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design Pleiotropic Role of HSF1 in Neoplastic Transformation
Current Cancer Drug Targets Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers
Current Gene Therapy